Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 754 | 28% |
| 2020 | 3 | 826 | 30% |
| 2021 | 5 | 850 | 32% |
| 2022 | 2 | 729 | 35% |
| 2023 | 3 | 702 | 38% |
| 2024 | 2 | 738 | 39% |
| 2025 from claims | – | 678 549–797 | 40% |
| 2026 forecast | – | 699 548–878 | 39% |
| 2027 forecast | – | 710 527–939 | 40% |
| 2028 forecast | – | 721 511–996 | 40% |
| 2029 forecast | – | 733 498–1,050 | 40% |
| 2030 forecast | – | 744 487–1,104 | 40% |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Massachusetts; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 91% inpatient hospital, 9% office. The share outside the hospital has moved +9 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 24 | 2,696−2.3%/yr | −2.3%/yr | 1.5 | 17% | 3,720 in 2030+5.5%/yr |
| Pennsylvania | 14 | 1,998+1.6%/yr | +1.6%/yr | 1.5 | 9% | 2,310 in 2030+2.4%/yr |
| New Jersey | 25 | 1,782+1%/yr | +1%/yr | 1.7 | 28% | 1,690 in 2030−0.8%/yr |
| Connecticut | 1 | 474−5.9%/yr | −5.9%/yr | 1.4 | 23% | 420 in 2030−1.9%/yr |
| New Hampshire | 0 | 145−3.6%/yr | −3.6%/yr | 0.6 | 0% | 220 in 2030+7.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 34 | 3,386−4.6%/yr | −4.6%/yr | 3.50.7× | 43% | 4,060 in 2030+3.1%/yr |
| Dialysis access | 31 | 2,905−7.2%/yr | −7.2%/yr | 3.20.5× | 22% | 3,070 in 2030+0.9%/yr |
| Superficial venous ablation | 31 | 1,623−5%/yr | −5%/yr | 1.70.5× | 94% | 1,600 in 2030−0.3%/yr |
| Carotid revascularization | 18 | 984−3.3%/yr | −3.3%/yr | 1.01.0× | 0% | 1,170 in 2030+2.9%/yr |
| Aortic endografts (EVAR/TEVAR) | 1 | 350−5.5%/yr | −5.5%/yr | 0.40.8× | 0% | 390 in 2030+1.8%/yr |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Penumbra leads with 54% of company spending on these surgeons in 2025, +14 pts on 2024.
In 2025, 15 companies reported engagement with Massachusetts’s surgeons worth $309K in consulting, speaking, meals and travel tied to these products, about $155K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.